Insider
Astrazeneca PLCAZN

AstraZeneca receives new regulatory approvals for rare diseases and cancer treatments

In the week ended November 16, 2026, AstraZeneca received several regulatory approvals, including EU authorization for Klygefa to treat myasthenia gravis. The company also announced US approval of Imfinzi for bladder cancer and a CHMP recommendation for Baxfendy to treat hypertension.

Verified against 4 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a long hallway with pictures on the walls
Photo by zhang shuaizhang on Unsplash
49%
Risk reduction in disease progression
15.7 mmHg
Reduction in systolic blood pressure
42%
Reduction in risk of death

Key points

  • The European Union approved Klygefa (gefurulimab) as an add-on therapy for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies.
  • The FDA approved Imfinzi in combination with enfortumab vedotin for adult patients with muscle-invasive bladder cancer who are ineligible for or refused cisplatin therapy.
  • On November 6, 2026, AstraZeneca officer Sharma Mani acquired one company share as part of a grant or award at a price of $186.24.

European Union approves Klygefa for myasthenia gravis treatment

The European Union approved Klygefa (gefurulimab) as an add-on therapy for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. The decision is based on the PREVAIL study, in which the drug showed statistically significant improvements in patient quality of life compared with a placebo. Klygefa is a complement C5 inhibitor that allows for once-weekly dosing by binding to serum albumin.

New approvals in oncology and cardiology

The FDA approved Imfinzi in combination with enfortumab vedotin for adult patients with muscle-invasive bladder cancer who are ineligible for or refused cisplatin therapy. An interim analysis of the VOLGA study showed a 49% reduction in the risk of disease progression, recurrence, surgery refusal, or death, as well as a 42% reduction in the risk of death.

The CHMP recommended EU approval for Baxfendy (baxdrostat) for patients with uncontrolled hypertension. The BaxHTN study showed a 15.7 mmHg reduction in systolic blood pressure at week 12 in the 2 mg dose group.

Insider transactions

On November 6, 2026, AstraZeneca officer Sharma Mani acquired one company share as part of a grant or award at a price of $186.24. Following this transaction, the individual holds 19,291.6989 shares.

Regulatory uncertainties

Despite positive clinical trial results, regulatory applications for Klygefa, Baxfendy, and the VOLGA regimen remain under review in China, Japan, and other countries. Further regulatory decisions on these applications are not yet known.

Future regulatory decisions

Shareholders should expect updates on registration applications for Baxfendy, Klygefa, and VOLGA-based therapeutic regimens in countries outside the EU and US. Information on these decisions will be provided in company regulatory filings.

Original sources

  1. 6-K filing, November 16, 2026November 16, 2026SHA-256 of our archived copy 22321b16cb67…
  2. 6-K filing, November 16, 2026November 16, 2026SHA-256 of our archived copy 1703e40f3e49…
  3. 6-K filing, November 16, 2026November 16, 2026SHA-256 of our archived copy 3882f5965b23…
  4. 4 filing, November 10, 2026November 10, 2026SHA-256 of our archived copy 6a6559951469…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards